<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800280</url>
  </required_header>
  <id_info>
    <org_study_id>A5361030</org_study_id>
    <nct_id>NCT00800280</nct_id>
  </id_info>
  <brief_title>Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body</brief_title>
  <official_title>A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of Steady-State Cimetidine On The Pharmacokinetics Of A Single Dose Of PD 0332334 In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the effects of multiple doses of cimetidine on the
      pharmacokinetics of a single dose of PD 0332334 and to evaluate the safety and tolerability
      of PD 0332334 when co-administered with cimetidine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:

      Additional Study Purpose Details: Evaluate the effects of multiple doses of cimetidine on the
      pharmacokinetics (e.g., elimination from the body) of a single dose of PD 0332334.

      On February 18th 2009, a decision to terminate further development for PD 0332334 was
      communicated to investigators in this study. The decision to terminate this study was not
      based on any safety concerns.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Please see Detailed Description for termination reason.
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PD 0332334 area under the curve (AUC) from 0 to infinity (AUCinf)</measure>
    <time_frame>4 to 6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PD 0332334 AUC from 0 to last quantifiable concentration (AUClast)</measure>
    <time_frame>4 to 6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2) of PD 0332334</measure>
    <time_frame>4 to 6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of PD 0332334</measure>
    <time_frame>4 to 6 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the incidence, duration and severity of adverse events</measure>
    <time_frame>4 to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the discontinuation due to adverse events</measure>
    <time_frame>4 to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical safety labs</measure>
    <time_frame>4 to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>4 to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>4 to 6 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Single dose PD 0332334</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose PD 0332334 with steady-state cimetidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD 0332334</intervention_name>
    <description>Single 300 mg dose of PD 0332334 immediate release capsules administered orally</description>
    <arm_group_label>Single dose PD 0332334</arm_group_label>
    <other_name>imagabalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD 0332334</intervention_name>
    <description>Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.</description>
    <arm_group_label>Single dose PD 0332334 with steady-state cimetidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cimetidine</intervention_name>
    <description>600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.</description>
    <arm_group_label>Single dose PD 0332334 with steady-state cimetidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy

          -  male or female adults

        Exclusion Criteria:

          -  Current or history of clinically significant medical illness

          -  Smokers

          -  Illicit drug use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5361030&amp;StudyName=Evaluating%20The%20Effects%20Of%20Cimetidine%20On%20The%20Elimination%20Of%20PD%200332334%20From%20The%20Body</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2008</study_first_submitted>
  <study_first_submitted_qc>December 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2008</study_first_posted>
  <last_update_submitted>February 16, 2010</last_update_submitted>
  <last_update_submitted_qc>February 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>cimetidine, PD 0332334, organic cation transporter, OCT2, pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

